MCA Stability Tool

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Zyloric 100mg tablets (Sigma Pharmaceuticals Plc)

Explore other Allopurinol formulations Explore other Allopurinol 100mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 100mg tablets (Aspen) and Allopurinol 100mg tablets (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Zyloric 300mg tablets (Aspen Pharma Trading Ltd)

Explore other Allopurinol formulations Explore other Allopurinol 300mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 300mg tablets (Aspen) and Allopurinol 300mg (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Zyloric 300mg tablets (Sigma Pharmaceuticals Plc)

Explore other Allopurinol formulations Explore other Allopurinol 300mg tablets suppliers

Stability Notes

Manufacturer recommends storing in original container. Protect from light. Anecdotal reports of use in MCAs (low quality evidence).

Provenance

This recommendation is based on the products Zyloric 300mg tablets (Aspen) and Allopurinol 300mg (Ipca Laboratories Ltd) and Allopurinol 200mg tablets (Aspire Pharma).

Use with caution

Zyprexa 10mg tablets (Abacus Medicine Ltd)

Explore other Olanzapine formulations Explore other Olanzapine 10mg tablets suppliers

Stability Notes

Hygroscopic. Protect from light and moisture. Can cause contact dermatitis, wear gloves if handling tablets. May discolour. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Eli Lilly and Accord Pharmaceuticals Ltd products.

Use with caution

Zyprexa 10mg tablets (CST Pharma Ltd)

Explore other Olanzapine formulations Explore other Olanzapine 10mg tablets suppliers

Stability Notes

Hygroscopic. Protect from light and moisture. Can cause contact dermatitis, wear gloves if handling tablets. May discolour. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Eli Lilly and Accord Pharmaceuticals Ltd products.

Use with caution

Zyprexa 10mg tablets (Necessity Supplies Ltd)

Explore other Olanzapine formulations Explore other Olanzapine 10mg tablets suppliers

Stability Notes

Hygroscopic. Protect from light and moisture. Can cause contact dermatitis, wear gloves if handling tablets. May discolour. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Eli Lilly and Accord Pharmaceuticals Ltd products.

Use with caution

Zyprexa 10mg tablets (Neon Healthcare Ltd)

Explore other Olanzapine formulations Explore other Olanzapine 10mg tablets suppliers

Stability Notes

Hygroscopic. Protect from light and moisture. Can cause contact dermatitis, wear gloves if handling tablets. May discolour. Max 28 days in MCA.

Provenance

Compatibility recommendation derived from Eli Lilly and Accord Pharmaceuticals Ltd products.

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.